Increase in food allergy patients U.S. approves first peanut allergy drug on the market.

Original title: Increase in food allergy patients U.S. approval of the first peanut allergy drug on the market
According to foreign media reported on the 2nd, the U.S. Food and Drug Administration (FDA) approved the first drug can be used to treat peanut allergy on the market. The drug, called AR101 and the trade name Palforzia, is designed to minimize the occurrence and severity of peanut allergic reactions in children.
reported that the drug was used as an oral immunotherapy. Children and adolescents with peanut allergies are required to take the drug continuously for 6 months at the direction of a doctor.
According to the Wall Street Journal, Palforzia is designed to allow patients to come into contact with allergens in small doses from an earlier source, so the main ingredient in the drug is extracted from peanut powder at a dose equivalent to a small amount of peanuts.
"Palforzia" is suitable for patients between the ages of 4 and 17 and is a powdered drug. After completing the first 6 months of treatment, the patient must continue to take the medicine once a day to prevent allergies caused by accidental peanut eating.
experts stress that the new drug can reduce the patient's allergic reaction after accidentally ingesting peanuts, but it will not cure peanut allergies. Experts also warn that even if they take the drug, patients may still experience allergic reactions or even die once exposed to peanuts. Therefore, after taking the medicine, patients should still try to avoid contact with peanuts in their daily diet.
the past few decades, more and more people in Western countries and regions have developed food allergies. Peanut allergy is one of the most common food allergies in the United States.
.